Literature DB >> 23183839

Polycystic kidney disease: Tolvaptan in ADPKD-TEMPO 3:4 trial results.

Rebecca Kelsey.   

Abstract

Entities:  

Year:  2012        PMID： 23183839     DOI： 10.1038/nrneph.2012.236

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  2 in total

1.  Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.

Authors:  V H Gattone; R L Maser; C Tian; J M Rosenberg; M G Branden
Journal:  Dev Genet       Date:  1999

2.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245
  2 in total
  4 in total

1.  Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan.

Authors:  Hirayasu Kai; Yuki Shinozaki; Airi Nishikubo; Megumi Watanabe; Takashi Tawara; Mamiko Iwase; Ryouya Tsunoda; Noriaki Moriyama; Toshiaki Usui; Tetsuya Kawamura; Kei Nagai; Masahiro Hagiwara; Chie Saito; Naoki Morito; Joichi Usui; Kunihiro Yamagata
Journal:  CEN Case Rep       Date:  2015-11-17

2.  Prediction of molecular interactions and physicochemical properties relevant for vasopressin V2 receptor antagonism.

Authors:  Ania de la Nuez Veulens; Yoanna M Álvarez Ginarte; Rolando E Rodríguez Fernandez; Fabrice Leclerc; Luis A Montero Cabrera
Journal:  J Mol Model       Date:  2022-01-07       Impact factor: 1.810

3.  Role of extracellular ATP and P2 receptor signaling in regulating renal cyst growth and interstitial inflammation in polycystic kidney disease.

Authors:  Gopi Rangan
Journal:  Front Physiol       Date:  2013-08-16       Impact factor: 4.566

Review 4.  An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases.

Authors:  Max Christoph Liebau
Journal:  Front Pediatr       Date:  2014-07-01       Impact factor: 3.418
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.